Meds, Mind, Body & Benefits > Research News & Studies

Sudhir Paul, Ph.D. UpDate

<< < (11/12) > >>

This fund rasing started in Dec 2011. Is for human trials. Previus raising was for pre clinical studies which have already taken place and this allows ARF to go foward to human trials.

Anyone else knows anything else about this?

I'm not sure if there's another thread re: abzyme research, but here's the thread I found, even though no one has posted anything in it in over 8 months.  I got an email yesterday from the Abzyme Research Foundation because I made a donation towards their $50,000 goal.  Here's what it said.

"I am thrilled to report that we hit our initial $50,000 goal!  Over 375 donors  came together to make our first presentation to the Federal Drug Administration (FDA) possible. I am incredibly thankful for your support, and very excited to take our first step towards receiving FDA approval for a new HIV/AIDS vaccine.
These funds will be used to employ Dr. Ellen Cooper as our chief FDA Regulatory Adviser. ARF is honored to work with such a prominent and respected figure in the field of HIV clinical studies.

Dr. Cooper is a graduate of Case Western (M.D.) and Johns Hopkins (M.P.H.), and her incredible achievements include:
·       Founding Director, Division of Antiviral Drug Products at the FDA (’88)
·       Vice President and Director, Department of Clinical Research and Information at AmFAR, and Chair, (’91-’93)
·       Chair, Therapeutics Coordinating Committee of the Office of AIDS Research at the National Institute of Health.  (’93-’96)
In short, we believe there isn’t anyone more qualified to lead an innovative new therapeutic vaccine through the complicated process of FDA approval for testing in humans.

Thanks for supporting us!  This year we tackle the FDA, next year a human trial!

All my best,
Zachary Barnett
Founder, Executive Director
Abzyme Research Foundation"

Thank you for making a donation:)

will this work against latent cells?

This is a "covalent vaccine" that produces antibodies or "enzymatic abzymes" that target a coat protein on HIV called gp120.  It's a region of HIV that does not mutate, so it is considered an achilles heel of HIV.  I don't know if the vaccine targets latent cells infected with HIV, but if the vaccine works in humans, the memory B-cells would bind to this region and destroy any active HIV before it infected new cells and ultimately eradicate the infection.  It has induced protective antibodies in mice, rabbits and rhesus monkeys according to the Abzyme Research Foundation.

If you enlarge the text in this link, you can see the data from studies in monkeys.

Cosmicdancer: Thanks for the links.

As a free monoclonal catalytic antibody, to my mind, would not have any effect on latently infected cells as they do not express/secrete viral particles until activated.

Since they are produced artificially outside the body they would not have any physical association with the host B cells and thus could not lead to memory cells expressing the catalytic antibody. 

But by altering the the structure of the HIV envelope gp120 they would allow access to other naturally occurring antibodies reactive to newly uncovered regions (epitopes) of the viral membrane. Binding of these, plus additional signals from other cells, of the immune system would allow those reactive B Cells cells to differentiate into activated B-Cells which in turn would become either memory B cells or antibody secreting plasma cells.

I haven't found anything about the half-life of these Mabs, perhaps others here have that answer.


[0] Message Index

[#] Next page

[*] Previous page

Go to full version